EUVIMEDEUVIMED entdecken
Crossref

Acquired Hemostasis Disorders

Antonella Tufano, Massimo Franchini, Antonio Coppola

Seminars in Thrombosis and Hemostasis · 2026-04 · 52 (03) · 277-279

DOI: 10.1055/a-2788-1844 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Seminars in Thrombosis and Hemostasis, online erschienen am 09.03.2026. Verfasst von Antonella Tufano und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This latest issue of Seminars in Thrombosis and Hemostasis (STH) is dedicated to acquired disorders of hemostasis, a broad and evolving group of conditions that significantly contribute to morbidity and mortality across all medical and surgical settings. Their clinical presentation, secondary to systemic disease, immune dysregulation, critical illness, malignancy, pregnancy-related conditions, or iatrogenic factors, including antithrombotic and anticancer drugs, is often abrupt and heterogeneous, ranging from life-threatening bleeding to complex and diffuse thrombotic phenotypes. In recent years, major advances refined our understanding of the mechanisms underlying these disorders, particularly those driven by autoantibodies, endothelial dysfunction, inflammation, and consumptive coagulopathies, in parallel with progress in laboratory diagnostics (including global coagulation assays) and therapeutic options (targeted hemostatic agents, factor concentrates, and reversal strategies for direct oral anticoagulants). However, timely recognition and optimal management remain challenging in most acquired bleeding and thrombotic clinical conditions. Aiming at providing a contemporary overview of some of these disorders, this issue includes 11 contributions by distinguished international experts, integrating pathophysiological updates with practical diagnostic considerations and current evidence about treatment. Notably, five articles in this issue deal with acquired hemophilia A (AHA), a rare bleeding disorder, but the most frequent and best studied among those due to acquired inhibitors of coagulation factors, in this case, autoantibodies neutralizing clotting activity and/or affecting the half-life of Factor VIII (FVIII).[ 1 ] Recently, case reports and clinical studies provided further insights into patient identification and, in particular, management optimization, which faces the dual challenge of hemostatic control and inhibitor eradication. In this respect, the FVIII mimetic bispecific monoclonal antibody emicizumab, first introduced for prophylaxis of bleeding in patients with congenital hemophilia A and inhibitors,[ 2 ] and is being increasingly reported to improve management of patients with AHA.[ 3 ] However, in keeping with the required format for issues of STH, the issue starts with a series of review articles. Among autoimmune factor deficiencies, acquired Factor XIII (FXIII) deficiency is associated with the highest hemorrhagic mortality rate, with patients showing extremely reduced FXIII levels and severe bleeding symptoms. Therefore, prompt recognition of this very rare disorder is crucial, but is challenged by poor awareness and frequent lack of adequate diagnostic assays. Pathophysiological, diagnostic, and treatment issues of acquired FXIII deficiency are comprehensively discussed in the review by Ichinose. Distinguishing autoimmune deficiency from other nonimmune reductions of FXIII, due to its reduced synthesis or accelerated clearance, like those related to liver cirrhosis, hematological or solid tumors, surgery, or trauma, is crucial. While the latter requires hemostatic treatment with FXIII concentrates, in autoimmune FXIII deficiency, similar to AHA, immunosuppressive treatment (IST) for inhibitor eradication is needed, with careful and long-term follow-up.[ 4 ] Positive lupus anticoagulant (LA) is classically associated with the thrombophilic antiphospholipid syndrome. However, in the rare lupus anticoagulant-hypoprothrombinemia syndrome (LA-HS), bleeding manifestations may occur due to the presence of autoantibodies against prothrombin (FII), causing a reduction of its plasma levels. The article by Barcellona et al[ 5 ] adds new information about LA-HS to that recently reviewed in this journal.[ 6 ] In the new report, the authors describe an old patient who developed severe bleeding and anemia after a lung fungal infection, showing positive LA, prolonged PT and APTT, reduced FII (15%) with the presence of FII inhibitor, and impaired thrombin generation. Bleeding was controlled by three-factor prothrombin complex concentrate, while IST with methylprednisolone led to normalization of coagulation tests after approximately 3 weeks. Moreover, 120 patients from a literature review were also analyzed, revealing the association in most cases with autoimmune or infectious diseases, age < 10 years in 40%, LA positive in all patients, and heterogeneous bleeding symptoms, mostly mucocutaneous (44%), severe in approximately 10% but also absent in 7.5% of patients. Neither hemostatic treatment nor IST is standardized.[ 5 ] Infection-related coagulation abnormalities play a relevant role in acquired bleeding and thrombotic disorders. As highlighted by Marietta et al, the recent Coronavirus disease 2019 (COVID-19) pandemic renewed attention on the impact of viral infections on the hemostatic system, resulting from direct interactions by viral components and immune-mediated processes. These pathophysiological mechanisms, effectively reviewed by the authors, include triggering of immune responses with the generation of proinflammatory cytokines, which contribute to endothelial dysfunction and coagulation activation, through effects on platelets, neutrophils, neutrophil extracellular traps, and the kallikrein-kinin system. The intensity of cytokine activation is responsible for the severity of clinical manifestations, while the timing and location of coagulation activation affect their type; indeed, initially localized phenomena may induce thrombotic response, like observed in COVID-19 in the lungs, followed by systemic hypercoagulation, whereas rapid diffuse activation progressing to consumptive coagulopathy results in bleeding complications, like in viral hemorrhagic fevers.[ 7 ] Coagulation abnormalities associated with COVID-19 are also discussed in the review by Franchini et al. They highlight the pivotal pathophysiological mechanism of the virus-induced endothelial injury/dysfunction, leading to an exaggerated inflammatory response and the cytokine storm. The consequent hemostatic unbalance by upregulation of procoagulants (i.e., increased tissue factor, fibrinogen, FVIII and von Willebrand Factor, platelet hyperactivation) and downregulation of anticoagulant and fibrinolytic pathways (i.e., reduced antithrombin and protein C, increased plasminogen activator inhibitor type 1) may trigger thromboembolic episodes; however, less frequently, bleeding complications may arise from virus-related autoimmune disorders, that is, immune thrombocytopenia and AHA, together with the use of anticoagulant prophylaxis or therapeutic doses in patients with COVID-19.[ 8 ] In the next chapter, Franchini and Mannucci review the coagulation abnormalities in patients with chronic liver disease (CLD) and their clinical implications. Such alterations affect both primary and secondary hemostasis, including prohemorrhagic (i.e., decreased coagulation factors, increased fibrinolysis, thrombocytopenia, and platelet dysfunction) and prothrombotic (i.e., decreased natural anticoagulants) changes. As a consequence of an unstable rebalanced hemostasis, CLD patients may experience both bleeding complications and thromboembolic events, often unpredictable and with highly challenging management. For these reasons, a close collaboration between hepatologists and coagulation specialists in the multidisciplinary patient follow-up is advised.[ 9 ] In the last review article of the issue, Wolfovitz et al address the rare but potentially life-threatening postpartum disseminated intravascular coagulation (DIC), which may complicate various obstetric conditions, including postpartum hemorrhage (PPH), intrauterine fetal death, placental abruption, and amniotic fluid embolism. The consumption of coagulation factors arises from the disruption of the delicate hemostatic balance during pregnancy, which physiologically tends toward hypercoagulability. The authors highlight the higher incidence of obstetric-related DIC in low-resource settings, due to delayed diagnosis and management of obstetric complications, and the role of preventive strategies, primarily the prompt recognition and treatment of PPH, in particular by the active management of the third stage of labor, the use of uterotonic agents, and of tranexamic acid. Also in this setting, careful multidisciplinary management is crucial for improving clinical outcomes.[ 10 ] We finish this issue of STH with the series of papers on AHA mentioned at the start of this Preface. These articles reflect varied clinical and research interests, with relevant information provided by Calcaterra et al, who present a retrospective real-world case series of five AHA patients treated with emicizumab, complemented by a systematic literature review resulting in a patient-level data analysis of 24 published cases. Data from these patients confirm the clinical benefits of early emicizumab treatment, which emerges as a potentially paradigm-shifting therapeutic option in AHA.[ 11 ] The other papers on AHA are Letters to the Editor, with three providing further data about the advantages of introducing emicizumab in the management of AHA patients. First, Pastore et al compare 11 “high-risk” patients (i.e., with negative predictors of remission and survival)[ 12 ] receiving early emicizumab treatment between late 2020 and 2024 at the Queensland Hemophilia Treatment Center in Brisbane (Australia) via a cost-sharing arrangement with the manufacturer, with a historical (2014–2018) matched group of 10 patients. Relevant reduction in total recombinant factor VIIa dose and duration of treatment, less frequent re-bleeding and new bleeding, and shorter length of hospitalization are shown in the emcizumab group, supporting the clinical and health economic benefits of such therapeutic option. Since emicizumab use in this setting remains off-label (except in Japan) and therefore unfunded, with consequent restrictions in early treatment and number of allowed doses, the authors highlight the need for the pursuit of a specific licensing in AHA.[ 13 ] Then, the letter by Gurumurthy et al reports the efficacy and safety of emicizumab in the challenging management of an old woman with multiple comorbidities, who experienced AHA with severe and recurrent bleeding, requiring prolonged and intensive treatment with activated prothrombin complex concentrate over 2 months. Due to the inadequate hemostatic control and infectious complications on combined IST, after off-label approval, emicizumab was started. The patient remained bleeding-free and was discharged 15 days later, on IST with steroids alone. Emicizumab was then used again for 11 weeks due to FVIII decline during the follow-up. This report highlights the additional potential benefit of emicizumab in reducing adverse events related to IST, allowing less aggressive treatment.[ 14 ] Finally, two letters report on patients with unusual clinical scenarios associated with FVIII inhibitors: Liu et al describe an old patient with advanced lung squamous cancer, treated with chemotherapy and immunotherapy with tislelizumab, a programmed death-1 inhibitor, diagnosed with AHA after 2 months, due to a notably prolonged activated partial thromboplastin time.[ 15 ] Tufano et al report a woman with a relapse of immune thrombotic thrombocytopenic purpura (iTTP; first episode 4 years earlier), who developed large hematomas and coagulation abnormalities leading to the diagnosis of AHA, while tapering steroids used for treating iTTP.[ 16 ] In both cases, an extensive immunologic derangement favored the autoimmunity against FVIII, and interactions between the coagulation and immune systems are suggested. Overall, by bringing together expert contributions from complementary disciplines, this issue seeks to support the readers in navigating the heterogeneity and complexity of acquired hemostatic disorders, addressing their mechanisms, identification, and management strategies. While wishing enjoyable reading, we would like to warmly thank all the authors who provided such excellent articles, the reviewers for their helpful comments and suggestions, and the Editorial Board of STH for the opportunity to develop this focused collection. Authors' Contributions A.T.: conceptualization, validation, and writing—review and editing. M.F.: validation and writing—review and editing. A.C.: conceptualization, validation, and writing—original draft, review, and editing. Publication History Received: 09 January 2026 Accepted: 13 January 2026 Article published online: 09 March 2026 © 2026. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

Autor:innen und Institutionen

  • Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.
  • Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy.
  • Regional Hub Center for Hemophilia and Congenital Bleeding Disorders, University Hospital of Parma, Parma, Italy.

Zitieren

APA

Tufano, A., Franchini, M., & Coppola, A. (2026). Acquired Hemostasis Disorders. Seminars in Thrombosis and Hemostasis, 52(03), 277-279. https://doi.org/10.1055/a-2788-1844

Vancouver

Tufano A, Franchini M, Coppola A. Acquired Hemostasis Disorders. Seminars in Thrombosis and Hemostasis. 2026;52(03):277-279. doi:10.1055/a-2788-1844

BibTeX
@article{Tufano2026,
  author = {Tufano, Antonella and Franchini, Massimo and Coppola, Antonio},
  title = {Acquired Hemostasis Disorders},
  journal = {Seminars in Thrombosis and Hemostasis},
  year = {2026},
  volume = {52},
  number = {03},
  pages = {277--279},
  doi = {10.1055/a-2788-1844}
}
Kostenlos starten →